Ocugen (OCGN) Preferred Stock Liabilities (2018 - 2019)
Ocugen's (OCGN) quarterly Preferred Stock Liabilities came in at $64347.0 in Q2 2019, down 90.99% YoY from $714041.0 in Q2 2018, and down 98.05% on a QoQ basis from $3.3 million in Q4 2018.
Ocugen (OCGN) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Ocugen (OCGN) has 2 years of Preferred Stock Liabilities data on file, last reported at $64347.0 in Q2 2019.
- Quarterly Preferred Stock Liabilities fell 90.99% year-over-year to $64347.0 in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $64347.0 (down 90.99% YoY) and the FY2018 annual result came in at $3.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities declined to $64347.0 in Q2 2019, from $3.3 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $3.3 million in Q4 2018 to a low of $64347.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 64,347.00 |
| Dec 31, 2018 | 3.29 Mn |
| Jun 30, 2018 | 714,041.00 |